Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: Results of a randomized phase 2 study

Autor:	Jong Seok Lee, Santiago Viteri Ramirez, Chester Lin, Ji-Youn Han, Harold N. Keer, Hye Ryun Kim, Antoinette J. Wozniak, In-Jae Oh, D. Ross Camidge, Mohammad Azab, Benjamin Besse, Dae Ho Lee, Joan H. Schiller, Myung-Ju Ahn, Nathan A. Pennell, Erin M. Bertino
Rok vydání:	2016
Předmět:	Cancer Research Crizotinib medicine.drug_class business.industry ALK-Positive Phases of clinical research respiratory tract diseases Hsp90 inhibitor ALK inhibitor 03 medical and health sciences 0302 clinical medicine Oncology hemic and lymphatic diseases 030220 oncology & carcinogenesis medicine Cancer research In patient Signal transduction business 030217 neurology & neurosurgery medicine.drug
Zdroj:	Journal of Clinical Oncology. 34:9059-9059
ISSN:	1527-7755 0732-183X
Popis:	9059Background: Crizotinib (C) was the first approved ALK inhibitor for use in in ALK positive (pos) NSCLC, but resistance ultimately develops through both ALK-related and other signaling pathways....
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::640a7fd6246651c83cb65d4b08c35d40 https://doi.org/10.1200/jco.2016.34.15_suppl.9059 Zobrazit plný text záznamu